Kyverna Therapeutics, Miv-cel, Mivocabtagene Autoleucel, KYV-101, CAR T-Cell Therapy, CD19, Stiff Person Syndrome, SPS, Multiple Sclerosis, Progressive Multiple Sclerosis

EMERYVILLE, Calif. — October 7, 2026 Kyverna Therapeutics announced that new clinical data for its investigational CD19 CAR T-cell...